Anzeige
Mehr »
Montag, 29.06.2026 - Börsentäglich über 12.000 News
China kontrolliert Seltene Erden - Brasilien könnte die Antwort sein
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PEFW | ISIN: KYG2588M1006 | Ticker-Symbol: PH4
Frankfurt
29.06.26 | 15:25
0,527 Euro
+9,74 % +0,047
Branche
Biotechnologie
Aktienmarkt
ASIEN
1-Jahres-Chart
CSTONE PHARMACEUTICALS CO LTD Chart 1 Jahr
5-Tage-Chart
CSTONE PHARMACEUTICALS CO LTD 5-Tage-Chart
RealtimeGeldBriefZeit
0,5400,55423:00
0,5260,56822:01

Aktuelle News zur CSTONE PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
CSTONE PHARMACEUTICALS Aktie jetzt für 0€ handeln
DoCSTONE PHARMA-B (02616): VOLUNTARY ANNOUNCEMENT - CSTONE PHARMACEUTICALS ENTERS INTO EXCLUSIVE COMMERCIALIZATION AGREEMENT WITH ARROTEX FOR SUGEMALIMAB ...3
MiCSTONE PHARMA-B (02616): NEXT DAY DISCLOSURE RETURN1
MiCSTONE PHARMA-B (02616): POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON JUNE 23, 20261
16.06.CSTONE PHARMA-B (02616): SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE CIRCULAR OF THE ANNUAL GENERAL MEETING4
15.06.CSTONE PHARMA-B (02616): NEXT DAY DISCLOSURE RETURN1
12.06.EQS Newswire: CStone Pharmaceuticals: CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody) ASCO 2026 Key Highlights579EQS Newswire / 12/06/2026 / 15:02 UTC+8 Shanghai - 12 Jun 2026 - The clinical datasets presented at ASCO 2026 further validate the trispecific synergistic mechanism of CS2009 and support its potential...
► Artikel lesen
12.06.CSTONE PHARMA-B (02616): VOLUNTARY ANNOUNCEMENT - CSTONE ANNOUNCES THE INITIATION OF GLOBAL PHASE I TRIAL OF CS5007 (EGFR/HER3 BISPECIFIC ADC)3
03.06.CSTONE PHARMA-B (02616): VOLUNTARY ANNOUNCEMENT - JOINT SHARE PURCHASE PLAN INITIATED BY THE DIRECTORS AND SENIOR MANAGEMENT1
01.06.CSTONE PHARMA-B (02616): FORM OF PROXY FOR ANNUAL GENERAL MEETING3
01.06.CSTONE PHARMA-B (02616): NOTICE OF ANNUAL GENERAL MEETING3
01.06.CSTONE PHARMA-B (02616): PROPOSALS FOR GENERAL MANDATES TO ISSUE AND BUY BACK SHARES, RE-ELECTION OF RETIRING DIRECTORS, RE-APPOINTMENT OF AUDITOR, PROPOSED ...4
01.06.CSTONE PHARMA-B Plans to Launch First Global Multi-center Phase III Trial of CS2009 by End-20268
01.06.CSTONE PHARMA-B (02616): VOLUNTARY ANNOUNCEMENT - ASCO 2026 | CSTONE PRESENTS LATEST CS2009 (PD-1/VEGF/CTLA-4 TRISPECIFIC ANTIBODY) CLINICAL DATA6
13.05.CSTONE PHARMA-B (02616): VOLUNTARY ANNOUNCEMENT - ON-MARKET SHARE REPURCHASE2
11.05.CSTONE PHARMA-B (02616): VOLUNTARY ANNOUNCEMENT - CSTONE INITIATES NATIONWIDE COMMERCIAL SUPPLY OF LOCALLY MANUFACTURED PRALSETINIB CAPSULES6
27.04.CSTONE PHARMA-B (02616): ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 20253
27.04.CSTONE PHARMA-B (02616): 2025 ANNUAL REPORT-
22.04.CSTONE PHARMA-B (02616): COMPLETION OF PLACING OF NEW SHARES UNDER GENERAL MANDATE1
22.04.CSTONE PHARMA-B (02616): NEXT DAY DISCLOSURE RETURN1
22.04.CSTONE PHARMA-B (02616): VOLUNTARY ANNOUNCEMENT - ASCO 2026 PREVIEW: CSTONE TO PRESENT UPDATED CLINICAL DATA FOR CS2009 (PD 1/VEGF/CTLA 4 TRISPECIFIC ...3
Weiter >>
40 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1